So the webinar revealed that major pharma are not interested in taking any of our DEP into Phase 3. Starpharma are now looking to attract smaller regional and country specific companies to take any DEP into Phase 3. Good luck with that.
I posted the following in early 2023. I believe it’s even more relevant today….
‘The concern is that if the current Pharma companies (Sanofi and Pfizer etc) that own the original and current marketed drugs, don’t want to licence the DEP versions of Docetaxel, Cabazitaxel and Irinotecan, (which they haven’t so far), who will?
Would a smaller company would want to take on the risk of spending the next 5 years and hundreds of millions of dollars developing a DEP version drug through Phase 3 and trying to attain marketing approval if there was a subsequent risk of patent infringement legal challenges from the big Pharma?
Perhaps this is the stumbling block and the hole in Starpharma’s internal DEP business model. Perhaps 10 years ago they thought Sanofi and Pfizer would be falling over themselves to get DEP, but was there a plan B if this didn’t occur?’
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)